Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ECT204 |
Synonyms | |
Therapy Description |
ECT204 are autologous human T-lymphocytes engineered to express an antibody-based antigen-binding domain targeting GPC3 and an effector-binding domain, which potentially lead to cytotoxic T-lymphocyte (CTL)-dependent killing of GPC3 expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ECT204 | ECT-204|ECT 204 | ECT204 are autologous human T-lymphocytes engineered to express an antibody-based antigen-binding domain targeting GPC3 and an effector-binding domain, which potentially lead to cytotoxic T-lymphocyte (CTL)-dependent killing of GPC3 expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04864054 | Phase Ib/II | ECT204 | T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA-3) | Recruiting | USA | 0 |